Our discoveries demonstrate DNMT3a and TET2 coordination as robust targets, whose disruption represents a promising strategy to increase the therapeutic efficacy of sorafenib in patients with refractory HCC. The gene discussed is TET2; the disease is hepatocellular carcinoma.